{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:30:24Z","timestamp":1777613424475,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01025","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:24:58Z","timestamp":1570620298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunomodulation in Cutaneous T Cell Lymphoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Martina","family":"Ferranti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Tadiotto Cicogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1684\/ejd.2017.3183","article-title":"Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study","volume":"28","author":"Maurelli","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.hoc.2018.08.003","article-title":"A review of primary cutaneous CD30+ lymphoproliferative disorders","volume":"33","author":"Chen","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1111\/ajt.12281","article-title":"Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series","volume":"13","author":"Se\u00e7kin","year":"2013","journal-title":"Am J Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1634\/theoncologist.2015-0242","article-title":"Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis","volume":"21","author":"Cordel","year":"2016","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clindermatol.2013.01.009","article-title":"Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies","volume":"31","author":"Mirvish","year":"2013","journal-title":"Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1136\/jim-2017-000636","article-title":"Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study","volume":"66","author":"Wang","year":"2018","journal-title":"J Investig Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8640","DOI":"10.1073\/pnas.94.16.8640","article-title":"Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells","volume":"94","author":"Schnierle","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/mthe.2001.0445","article-title":"A packaging cell line generating CD4-specific retroviral vectors for efficient gene transfer into primary human T-helper lymphocytes","volume":"4","author":"Thaler","year":"2001","journal-title":"Mol Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1525-0016(03)00241-7","article-title":"MLV\/HIV-pseudotyped vectors: a new treatment option for cutaneous T cell lymphomas","volume":"8","author":"Thaler","year":"2003","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20047","DOI":"10.1074\/jbc.R700004200","article-title":"The interferons: 50 years after their discovery, there is much more to learn","volume":"282","author":"Pestka","year":"2007","journal-title":"J Biol Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.det.2015.05.008","article-title":"The use of interferons in the treatment of cutaneous T-cell lymphoma","volume":"33","author":"Spaccarelli","year":"2015","journal-title":"Dermatol Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.1002\/jcp.27816","article-title":"Immune checkpoint blockade opens a new way to cancer immunotherapy","volume":"234","author":"Sadreddini","year":"2018","journal-title":"J Cell Physiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am J Dermatopathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14712598.2017.1369951","article-title":"Monoclonal antibodies against cutaneous T-cell lymphomas","volume":"17","author":"Alaibac","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","article-title":"Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma","volume":"1","author":"Bar-Sela","year":"2015","journal-title":"JAAD Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jdcr.2018.01.016","article-title":"Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma","volume":"4","author":"Zheng","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"Onco Targets Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrclinonc.2015.142","article-title":"Haematological cancer: resiquimod\u2014a topical CTCL therapy","volume":"12","author":"Killock","year":"2015","journal-title":"Nat Rev Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T19:36:18Z","timestamp":1721849778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":25,"alternative-id":["10.3389\/fonc.2019.01025"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01025","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"article-number":"1025"}}